Last reviewed · How we verify
Topical Clotrimazole cream
Clotrimazole inhibits fungal cell membrane synthesis by blocking ergosterol production, disrupting the integrity and function of the fungal cell membrane.
Clotrimazole inhibits fungal cell membrane synthesis by blocking ergosterol production, disrupting the integrity and function of the fungal cell membrane. Used for Topical fungal infections including tinea pedis (athlete's foot), Tinea corporis (ringworm), Tinea cruris (jock itch).
At a glance
| Generic name | Topical Clotrimazole cream |
|---|---|
| Sponsor | Hayat Abad Medical Complex, Peshawar |
| Drug class | Imidazole antifungal |
| Target | Fungal lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Clotrimazole is an imidazole antifungal that inhibits the fungal cytochrome P450 enzyme lanosterol 14α-demethylase, which is essential for converting lanosterol to ergosterol. Ergosterol is a critical component of the fungal cell membrane; its depletion leads to increased membrane permeability and leakage of cellular contents, ultimately causing fungal cell death. The topical formulation delivers the drug directly to affected skin surfaces with minimal systemic absorption.
Approved indications
- Topical fungal infections including tinea pedis (athlete's foot)
- Tinea corporis (ringworm)
- Tinea cruris (jock itch)
- Candidiasis (yeast infections)
- Pityriasis versicolor
Common side effects
- Local irritation or burning at application site
- Erythema
- Pruritus
- Contact dermatitis
Key clinical trials
- Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract (EARLY_PHASE1)
- Alternation in the Human Microbiome With Commonly Used Topical Medications (PHASE1)
- Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. (PHASE3)
- Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis (PHASE4)
- Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment (PHASE1)
- Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated (PHASE2, PHASE3)
- Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris (PHASE2)
- Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Clotrimazole cream CI brief — competitive landscape report
- Topical Clotrimazole cream updates RSS · CI watch RSS
- Hayat Abad Medical Complex, Peshawar portfolio CI